Volume 17, Issue S10 e054948
PUBLIC HEALTH
Free Access

When is more better? Modeling the effect of dose on the efficacy of the MAPT multidomain intervention as a function of individual characteristics

Sylvie Belleville

Corresponding Author

Sylvie Belleville

Research Centre, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada

Correspondence

Sylvie Belleville, Research Centre, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada

Email: [email protected]

Search for more papers by this author
Simon Cloutier

Simon Cloutier

Research Centre, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada

Search for more papers by this author
Samira Mellah

Samira Mellah

Research Centre, Institut Universitaire de Gériatrie de Montréal, Montreal, QC, Canada

Search for more papers by this author
Sherry L Willis

Sherry L Willis

University of Washington, Seattle, WA, USA

Search for more papers by this author
Bruno Vellas

Bruno Vellas

Institute of Aging, Toulouse University Hospital - UMR, 1295, Toulouse, France

Search for more papers by this author
Nicola Coley

Nicola Coley

INSERM, University of Toulouse, Toulouse, France

Search for more papers by this author
Sandrine Andrieu

Sandrine Andrieu

Institute of Aging, Toulouse University Hospital - UMR, 1295, Toulouse, France

Search for more papers by this author
Tiia Ngandu

Tiia Ngandu

Karolinska Institutet, Stockholm, Sweden

Search for more papers by this author
MAPT/DSA Group
First published: 31 December 2021
Citations: 1

Abstract

Background

Dose is a critical factor examined in pharmacological treatment. However, little is known about the optimal dosage for non-pharmacological multidomain interventions as well as the function that relates dose to improvement. These gaps have been assessed in this present study in interaction with individual characteristics, which may moderate the effect of dose. Magnification models predict that healthier individuals will benefit more from prolonged practice, whereas reserve models predict that training will reduce cognitive disadvantage.

Method

The data from the Multidomain Alzheimer Preventive Trial (MAPT) was used to determine the relationship between cognitive training dose and cognition, and its interaction with sex, age, education, entry criteria, CAIDE risk score, frailty and Apoe4 status. The MAPT is a three-year randomized controlled trial, which includes cognitive training, physical activity, nutrition and omega-3 polyunsaturated fatty acids in at-risk individuals. The number of hours of cognitive training attended (max.=28) was used as a measure of dose in the 749 participants randomized to the multidomain intervention.

Result

First, polynomial regression analysis modelled cognitive performance over time on memory, verbal fluency and composite cognitive score. Mixed model analyses measured the effect of dose on expected scores, and interaction with individual factors were assessed. A cubic function explained the relationship between dose and performance indicating benefits up to 12-14 training hours followed by a plateau. Interactions were found with individual characteristics. Older participants and those with a higher CAIDE score reached their plateau more rapidly. Individuals with lower education and frail individuals benefited more from increased exposure.

Conclusion

A non-linear dose-response function indicates that more is not necessarily better. Here, the optimal dose was found to be 12-14 hours of training, about half of what was potentially available to participants. A magnification effect is found for age and vascular risk factors as younger and healthier participants show larger benefit. However, a reserve effect is found in frail or less educated participants as they benefitted more from additional training experience than their more privileged counterparts.